Table 2.
Genotype-specific regulatory gene networks altered in progressive HCV liver injury.
| Diseases and functions gene network | Ratio* | −log10 (p-value)^ |
|---|---|---|
| HCV genotype 3 vs genotype 1 | ||
| Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry (A) | 18/33 | 8 |
| Cellular Development, Cellular Growth and Proliferation, Organ Development (A) | 4/7 | 2 |
| HCV genotype 1 vs NDL | ||
| Lipid Metabolism, Small Molecule Biochemistry, Vitamin and Mineral Metabolism (A) | 35/35 | 13 |
| Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry (B) | 17/22 | 2 |
| Cellular Development, Cellular Growth and Proliferation, Organ Development (B) | 6/8 | 1 |
| Cell Death and Survival, Gastrointestinal Disease, Hepatic System Disease | 4/6 | 1 |
| HCV genotype 3 vs NDL | ||
| Lipid Metabolism, Small Molecule Biochemistry, Vitamin and Mineral Metabolism (B) | 15/17 | 5 |
| Lipid Metabolism, Small Molecule Biochemistry, Vitamin and Mineral Metabolism (C) | 16/25 | 2 |
| Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry (C) | 14/25 | 1 |
| Cellular Development, Cellular Growth and Proliferation, Organ Development (C) | 5/7 | 1 |
| Cancer, Cell Death and Survival, Organismal Injury and Abnormalities | 3/4 | 1 |
*Ratio: The number of differentially expressed genes (up- or down-regulated), when compared with the total number of genes within a specified canonical pathway, as defined by Ingenuity Pathways Analysis; ^Score = −log10(p-value); only those networks with at least three focus molecules, as well as a −log10(p-value) ≥1 in the network are included in the analysis. Letters refer to a unique network with the same gene ontology.